RE:Read The first company mentioned in the article Great find, Ric. Given the Clovis precedent, I think Pli has a real chance to early approval of 4050 in the Alstrom and IPF applications based on open label studies provided follow up Phase 3 studies are done. In the case of IPF perhaps a larger open label trial will be required but who knows. This precedent along with the New Cures Act is going to give Pli accelerated approval pathways.